{"pmid":32500936,"title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.","text":["Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.","Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 55.5+/-8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75+/-2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days respectively; in both patient a significant increase of total lymphocyte count was observed. In conclusion KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19 associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.","Transpl Infect Dis","Mella, Alberto","Mingozzi, Silvia","Gallo, Ester","Lavacca, Antonio","Rossetti, Maura Maria","Clari, Roberta","Randone, Olga","Maffei, Stefano","Salomone, Mario","Imperiale, Daniele","Biancone, Luigi","32500936"],"abstract":["Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 55.5+/-8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75+/-2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days respectively; in both patient a significant increase of total lymphocyte count was observed. In conclusion KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19 associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population."],"journal":"Transpl Infect Dis","authors":["Mella, Alberto","Mingozzi, Silvia","Gallo, Ester","Lavacca, Antonio","Rossetti, Maura Maria","Clari, Roberta","Randone, Olga","Maffei, Stefano","Salomone, Mario","Imperiale, Daniele","Biancone, Luigi"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500936","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13348","e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668804508723970048,"score":9.490897,"similar":[{"pmid":32471001,"title":"COVID-19 in elderly kidney transplant recipients.","text":["COVID-19 in elderly kidney transplant recipients.","The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate.","Am J Transplant","Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio","32471001"],"abstract":["The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate."],"journal":"Am J Transplant","authors":["Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32471001","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/ajt.16096","locations":["obese"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668167109982552064,"score":316.0917},{"pmid":32337859,"title":"Two distinct cases with COVID-19 in kidney transplant recipients.","text":["Two distinct cases with COVID-19 in kidney transplant recipients.","The fatality of novel coronavirus disease (COVID-19) is precipitously increased in patients with underlying comorbidities or elderly people. Kidney transplant (KT) recipients are one of the vulnerable populations for infection. COVID-19 infection in KT recipients might be a complicated and awkward situation, but there has been a lack of reports concerning this group. Herein, we demonstrated two distinct cases with different clinical progress. The first case was a 36-year-old man who underwent KT 3 years ago. He was diagnosed with COVID-19 expressing relevant symptoms. Following administration of lopinavir/ritonavir and hydroxychloroquine with reduced immunosuppressant, he recovered from COVID-19. However, the unexpected fluctuations in tacrolimus trough levels needed to be managed because of drug-to-drug interaction. The second case was developed in a 56-year-old man without any symptoms. He took the second KT from an ABO-incompatible donor 8 years ago. He was diagnosed with COVID-19 by screening due to exposure history. During the hospitalization period, the chest infiltrative lesion showed a wax and wane, but he successfully recovered by hydroxychloroquine with azithromycin. These apparently different cases suggest that assertive screening and management could improve the clinical course. In addition, antiviral agents should be used cautiously, especially in patients on calcineurin inhibitors.","Am J Transplant","Kim, Yaerim","Kwon, Ohyun","Paek, Jin Hyuk","Park, Woo Yeong","Jin, Kyubok","Hyun, Miri","Lee, Ji Yeon","Kim, Hyun Ah","Han, Seungyeup","32337859"],"abstract":["The fatality of novel coronavirus disease (COVID-19) is precipitously increased in patients with underlying comorbidities or elderly people. Kidney transplant (KT) recipients are one of the vulnerable populations for infection. COVID-19 infection in KT recipients might be a complicated and awkward situation, but there has been a lack of reports concerning this group. Herein, we demonstrated two distinct cases with different clinical progress. The first case was a 36-year-old man who underwent KT 3 years ago. He was diagnosed with COVID-19 expressing relevant symptoms. Following administration of lopinavir/ritonavir and hydroxychloroquine with reduced immunosuppressant, he recovered from COVID-19. However, the unexpected fluctuations in tacrolimus trough levels needed to be managed because of drug-to-drug interaction. The second case was developed in a 56-year-old man without any symptoms. He took the second KT from an ABO-incompatible donor 8 years ago. He was diagnosed with COVID-19 by screening due to exposure history. During the hospitalization period, the chest infiltrative lesion showed a wax and wane, but he successfully recovered by hydroxychloroquine with azithromycin. These apparently different cases suggest that assertive screening and management could improve the clinical course. In addition, antiviral agents should be used cautiously, especially in patients on calcineurin inhibitors."],"journal":"Am J Transplant","authors":["Kim, Yaerim","Kwon, Ohyun","Paek, Jin Hyuk","Park, Woo Yeong","Jin, Kyubok","Hyun, Miri","Lee, Ji Yeon","Kim, Hyun Ah","Han, Seungyeup"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337859","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15947","e_drugs":["Hydroxychloroquine","Azithromycin","lopinavir-ritonavir drug combination","Tacrolimus"],"topics":["Case Report"],"weight":1,"_version_":1666138494241603584,"score":294.21344},{"pmid":32397399,"title":"Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).","text":["Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).","Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.","Microorganisms","Colaneri, Marta","Bogliolo, Laura","Valsecchi, Pietro","Sacchi, Paolo","Zuccaro, Valentina","Brandolino, Fabio","Montecucco, Carlomaurizio","Mojoli, Francesco","Giusti, Emanuele Maria","Bruno, Raffaele","The Covid Irccs San Matteo Pavia Task Force","32397399"],"abstract":["Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19."],"journal":"Microorganisms","authors":["Colaneri, Marta","Bogliolo, Laura","Valsecchi, Pietro","Sacchi, Paolo","Zuccaro, Valentina","Brandolino, Fabio","Montecucco, Carlomaurizio","Mojoli, Francesco","Giusti, Emanuele Maria","Bruno, Raffaele","The Covid Irccs San Matteo Pavia Task Force"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397399","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/microorganisms8050695","keywords":["covid-19 pneumonia","icu","mortality rate","off label therapy","propensity score matching","tocilizumab"],"locations":["Pavia","Italy","Tocilizumab"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Azithromycin","Hydroxychloroquine","tocilizumab","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666714494985830400,"score":280.91772},{"pmid":32376398,"title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.","text":["Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.","A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8mg/kg by two consecutive intravenous infusions 12h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in ARDS assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24-72h and 10days after tocilizumab administration. Out of 100 treated patients (88M, 12F; median age: 62years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0-2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS>/=7 before TCZ). Overall at 10days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and interleukin 6 (IL-6) indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.","Autoimmun Rev","Toniati, Paola","Piva, Simone","Cattalini, Marco","Garrafa, Emirena","Regola, Francesca","Castelli, Francesco","Franceschini, Franco","Foca, Emanuele","Andreoli, Laura","Latronico, Nicola","32376398"],"abstract":["A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8mg/kg by two consecutive intravenous infusions 12h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in ARDS assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24-72h and 10days after tocilizumab administration. Out of 100 treated patients (88M, 12F; median age: 62years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0-2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS>/=7 before TCZ). Overall at 10days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and interleukin 6 (IL-6) indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement."],"journal":"Autoimmun Rev","authors":["Toniati, Paola","Piva, Simone","Cattalini, Marco","Garrafa, Emirena","Regola, Francesca","Castelli, Francesco","Franceschini, Franco","Foca, Emanuele","Andreoli, Laura","Latronico, Nicola"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376398","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102568","locations":["Brescia","Italy","Brescia","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666262687630229504,"score":274.94815},{"pmid":32478465,"title":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.","text":["First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.","BACKGROUND AND AIMS: Tocilizumab (TCZ; interleukine-6 receptor antagonist) has been proposed to treat severe forms of Coronavirus disease-19 (COVID-19) because interleukine-6 plays an important role in COVID-19-induced cytokine storm. Several clinical studies have shown very good effects of TCZ in patients with COVID-19, with a few minor side effects reported. Only eight serious liver injuries caused by TCZ were reported before being used in the treatment of patients with COVID-19. Considering the significantly increased use of TCZ for the treatment of COVID-19, we would like to warn of its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs. METHODS: We describe a patient with COVID-19-induced cytokine storm who developed drug-induced liver injury associated with the use of TCZ. RESULTS: One day after TCZ administration, serum transaminase levels increased 40-fold. Nevertheless, TCZ had a positive effect on clinical and laboratory parameters in cytokine storm, with transaminases values normalizing in 10 days. CONCLUSIONS: This is the first reported case of DILI caused by TCZ in a COVID-19 patient. Intensive liver function monitoring is imperative in COVID-19 patients, because of frequent polypharmacy with potentially hepatotoxic drugs.","Liver Int","Muhovic, Damir","Bojovic, Jelena","Bulatovic, Ana","Vukcevic, Batric","Ratkovic, Marina","Lazovic, Ranko","Smolovic, Brigita","32478465"],"abstract":["BACKGROUND AND AIMS: Tocilizumab (TCZ; interleukine-6 receptor antagonist) has been proposed to treat severe forms of Coronavirus disease-19 (COVID-19) because interleukine-6 plays an important role in COVID-19-induced cytokine storm. Several clinical studies have shown very good effects of TCZ in patients with COVID-19, with a few minor side effects reported. Only eight serious liver injuries caused by TCZ were reported before being used in the treatment of patients with COVID-19. Considering the significantly increased use of TCZ for the treatment of COVID-19, we would like to warn of its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs. METHODS: We describe a patient with COVID-19-induced cytokine storm who developed drug-induced liver injury associated with the use of TCZ. RESULTS: One day after TCZ administration, serum transaminase levels increased 40-fold. Nevertheless, TCZ had a positive effect on clinical and laboratory parameters in cytokine storm, with transaminases values normalizing in 10 days. CONCLUSIONS: This is the first reported case of DILI caused by TCZ in a COVID-19 patient. Intensive liver function monitoring is imperative in COVID-19 patients, because of frequent polypharmacy with potentially hepatotoxic drugs."],"journal":"Liver Int","authors":["Muhovic, Damir","Bojovic, Jelena","Bulatovic, Ana","Vukcevic, Batric","Ratkovic, Marina","Lazovic, Ranko","Smolovic, Brigita"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478465","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/liv.14516","keywords":["covid-19","sars-cov-2","drug-induced liver injury","hepatotoxicity","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668437834911973376,"score":271.5672}]}